Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that belimumab helped achieve low disease activity in over 40% of systemic lupus erythematosus patients in real-life settings, alongside reduced corticosteroid use and fewer flares.

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.

This study documented a variety of skin lesions in COVID-19 patients, indicating that skin rashes might be an early or sole symptom of the disease.

Syphilis can cause hair loss without other symptoms and should be considered when diagnosing unexplained hair loss.

This study reported that belimumab helped over 40% of active systemic lupus erythematosus patients achieve low disease activity, with more than 20% able to stop glucocorticoids completely.